could well be right - either way they have DA approval and $2.5m allocated to the facility with plans for it to be operational by (calendar) year end.
I feel for people not understanding the licences as first thing I researched and why compared to Cann group (CAN) from valuation perspective. Mr Market would be playing on the ignorance of many and yes the wording whilst not a lie in the announcement could be construed as somewhat confusing / misleading for those who don't understand what the licences mean.
Having a cultivation and production licence is very valuable in itself and if you follow CAN as I have in the past you would understand that.
- Forums
- ASX - By Stock
- CGB
- Ann: Q&A on the merger of QBL MCL and Medcan
Ann: Q&A on the merger of QBL MCL and Medcan, page-318
-
- There are more pages in this discussion • 231 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online